A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
2상
진행 중(모집 완료)
NCT02519348
| 대상 질환 | Hepatocellular Carcinoma |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | MedImmune LLC |
|---|
| 상태 | 진행 중(모집 완료) |
|---|
| 참여자 수 | 433 명 |
|---|
| 중재(약물) | Tremelimumab, Durvalumab, Bevacizumab |
|---|
| 시작일 | 2015년 10월 19일 |
|---|
| 완료일 | 2020년 11월 6일 |
|---|
| 결과 공개일 | 2021년 12월 6일 |
|---|
요약
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.
Number of Participants With Dose Limiting Toxicities (DLTs)
From Day 1 to Day 28 after first dose of study drug · Participants
| Part 1A: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 0 Participants |
|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) · Participants
| Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 38 Participants |
|---|
| Parts 2 and 3: Durvalumab 1500 mg | 95 Participants |
|---|
| Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg | 73 Participants |
|---|
| Parts 2 and 3: Tremelimumab 750 mg | 67 Participants |
|---|
| Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg | 80 Participants |
|---|
| Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg | 45 Participants |
|---|
Number of Participants With Clinically Important Changes in Hematology and Clinical Chemistry Parameters
From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) · Participants
| Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 0 Participants |
|---|
| Parts 2 and 3: Durvalumab 1500 mg | 5 Participants |
|---|
| Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg | 6 Participants |
|---|
| Parts 2 and 3: Tremelimumab 750 mg | 6 Participants |
|---|
| Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg | 6 Participants |
|---|
| Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.